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Purpose: To evaluate the effect of glucocorticoids on the expression and function of Toll-like receptors (TLRs) in human
corneal fibroblasts (HCFs).
Methods: Cultured HCF cells were stimulated with three different concentrations of hydrocortisone. The effect on the
expression of TLR2 and TLR4 was determined by real-time PCR. The TLR2, TLR4, and pIκB-α proteins were compared
by western blot. The release of IL-6 and IL-8 was measured using enzyme-linked immunosorbent assay in the presence
and absence of TLR2 and TLR4-specific blocking antibodies.
Results: Incubation of HCFs with hydrocortisone markedly inhibited the expression of TLR2 and TLR4 mRNAs and
decreased the release of IL-6 and IL-8 in a dose-dependent manner. Western blot analysis confirmed that expression of
TLR2, TLR4, and pIκB-α was also downregulated in response to hydrocortisone. The result of ELISA also showed the
release of IL-6 and IL-8 can also be inhibited by hydrocortisone. However, all these inhibitions were counteracted after
pretreatment with anti-TLR2 and anti-TLR4 monoclonal antibodies.
Conclusions: Glucocorticoids, such as hydrocortisone, can inhibit the expression of TLR2 and TLR4 on HCFs, and thus
may increase susceptibility to cornea infections. Our results suggest that topical glucocorticoids may affect the cornea’s
innate immunity through TLRs.
The corneal innate immune system consists of multiple
cell types. The first layer of defense is the corneal epithelium.
Immediately beneath this layer of epithelial cells is the stromal
layer  (fibroblasts  are  the  principal  cellular  component),
followed by an innermost single layer of endothelial cells.
Corneal  fibroblasts  probably  contribute  to  the  local
accumulation and activation of leukocytes in the cornea, and
play  an  important  role  in  infectious  inflammation  [1,2].
Recently, Toll-like receptors (TLRs) have been shown to play
an essential role in triggering the innate immune response by
recognizing  pathogen-associated  molecular  patterns
(PAMPs), and in stimulating the activity of host immune cells
against several microbial products [3]. A growing number of
studies have shown that TLR1-10s are expressed on both
human corneal epithelium and fibroblasts [4-6], and that they
play an important role in cornea protection and defense against
microbial infection [4,6-9].
Glucocorticoids are widely recognized as regulators of
adaptive  immunity  and  inflammation  and  have  been
extensively  used  clinically  to  suppress  a  large  variety  of
inflammatory  and  immune  responses  [10].  Topically,
corticosteroids are the most widely used agents and are the
standard treatment of nearly every inflammatory disease of
the  anterior  segment  [11,12].  The  molecular  and  cellular
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mechanisms  involved  in  the  anti-inflammatory  actions  of
glucocorticoids are now becoming clearer. However, there is
no convincing evidence that topical glucocorticoids suppress
innate  immune  responses  in  the  cornea  or  increase
susceptibility to cornea infections.
In  this  study,  we  investigated  the  effects  of
hydrocortisone on the expression of TLR2 and TLR4 in human
corneal fibroblast cells (HCFs). The results demonstrated that
the  functional  expression  of  TLR2  and  TLR4  is  greatly
downregulated in HCFs by hydrocortisone. However, these
inhibitions can be counteracted after pretreatment with anti-
TLR2 and anti-TLR4 monoclonal antibodies. These findings
provide evidence for the important role of glucocorticoids on
infection  keratitis  and  indicate  that  the  use  of  topical
glucocorticoids  may  affect  the  cornea’s  innate  immunity
through TLRs.
METHODS
Reagents  and  antibodies:  Dulbecco’s  Modified  Eagle
Medium,  F12,  fetal  bovine  serum  (FBS),  and  phosphate-
buffered saline (PBS) were obtained from Invitrogen-Gibco
(New York, NY). All media and cytokines used for cell culture
were endotoxin-minimized. Tissue culture dishes and six-well
chamber  slides  were  from  BD  (New  York,  NY).
Hydrocortisone was obtained from Calbiochem (Darmstant,
Germany). Affinity-purified, monoclonal, anti-human TLR2,
TLR4, and normal mouse immunoglobulin G (IgG) were from
eBioscience (San Diego, CA). Paired antibodies for human
interleukin-6 (IL-6) and IL-8 enzyme-linked immunosorbent
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2435assays  (ELISA)  were  from  BD.  RNeasy  Mini  kits  were
purchased from Qiagen (Valencia, CA) for RNA extraction.
RNA  PCR  kits  were  from  Promega  (Fitchburg,  WI),  and
ethidium bromide, DNA molecular size markers, and agarose
were from Gene Tech (Shanghai, China). SYBR Green PCR
kits were from Applied Biosystems (Foster City, CA).
Isolation  and  culture  of  human  corneal  fibroblasts:  Four
human corneas were obtained from the Eye Bank of Wenzhou
Medical College (Wenzhou, China). The donors were Chinese
males and females ranging in age from 23 to 28 years. After
the center of each donor cornea was punched out for corneal
transplantation surgery, the remaining rim of the tissue was
used for the present experiments. Human material was used
in  strict  accordance  with  the  basic  principles  of  the
Declaration of Helsinki. Corneal fibroblasts were prepared
and cultured as described previously [13]. Each cornea was
digested separately with collagenase to provide a suspension
of  corneal  fibroblasts.  The  cells  from  each  cornea  were
cultured independently in DMEM supplemented with 20%
FBS  in  60  mm  dishes  until  they  had  achieved  ≥90%
confluence, then these digested cells were moved from the 60
mm dishes to a 25 cm2 culture flask. They were used for the
present study after four to six passages. Purity of the corneal
fibroblast cultures was judged on the basis of cell morphology
and reactivities with antibodies to cytokeratin, as previously
described [14]. All the cells were negative for cytokeratin,
suggesting  that  the  cultures  were  not  contaminated  by
epithelial cells.
Cell  challenge:  The  cells  were  stimulated  with  different
concentrations of hydrocortisone (1, 10, or 100 μg/ml). For
extracting  total  RNA,  the  cells  were  incubated  under  the
stimulation of hydrocortisone for 48 h at 37 °C, and then
harvested. For ELISA, the supernatants were incubated under
the stimulation of hydrocortisone for 48 h at 37 °C, then
collected and stored at −80 °C after centrifugation, until use.
TLR blocking experiments were conducted by incubating
HCFs with monoclonal antibodies against TLRs. HCFs were
incubated at room temperature with either anti-TLR4, anti-
TLR2,  both  anti-TLR4  and  anti-TLR2,  or  IgG  control
antibodies for 60 min. Cells were then treated with hyphal
fragments  for  48  h  at  37  °C,  and  the  supernatants  were
collected in order to evaluate the releases of IL-6 and IL-8.
Real-time  PCR:  Total  RNA  prepared  from  confluent
monolayers of HCFs was used to evaluate the constitutive
expression of TLR2 and TLR4 mRNA. A negative control (the
PCR without a preceding RT step) for each sample was run in
order to assess whether there was residual genomic DNA in
the DNase-treated samples. Real-time PCR was performed in
an ABI PRISM 7500 Sequence Detection System Thermal
Cycler (Applied Biosystems). Real-time PCR was performed
on a volume of 15 μl containing 1.5 μl (50 ng) of cDNA and
13.5 μl of master mix containing 7.5 μl of mix (SYBR Green
PCR Master Mix, Applied Biosystems, UK), 0.75 μl of each
primer (10 pmol/l), and 4.5 μl of diethyl pyrocarbonate-treated
water. The primers are listed in Table 1. The program was set
at 50 °C for 2 min and 95 °C for 10 min, followed by 40 cycles
of denaturation at 95 °C for 15 s, and annealing at 60 °C for
60  s.  The  melting  curve  was  analyzed  by  elevating  the
temperature  from  60  °C  to  95  °C  while  monitoring
ﬂuorescence. SYBR green ﬂuorescence was monitored after
each elongation period. Samples were ampliﬁed with GAPDH
primers for determination of the initial relative quantity of
cDNA  in  each  sample,  and  then  all  PCR  products  were
normalized  to  that  amount.  Negative  controls  (without
template) were produced for each run.
Samples  were  amplified  in  triplicate,  averages  were
calculated,  and  differences  in  Ct  data  were  evaluated  by
Sequence Detection Software V1.3.1 (Applied Biosystems).
For data analysis, we used the comparative Ct method (ΔΔCt
method) with the following formula: ΔCt=Ct (Target, TLR)
−  Ct  (Endo,  GAPDH).  The  comparative  ΔΔCt  calculation
involved finding the difference between the ΔCt of treated cells
and the mean value of the ΔCt from the untreated cells. Fold
increase in the expression of specific mRNA in treated cells
compared to untreated cells was calculated as 2-(ΔΔCt). Data are
expressed as relative quantities (RQs), and differences are
shown in the ﬁgures as the expression ratio of the normalized
target gene, according to the software results.
Immunofluorescent staining: HCFs were seeded onto Lab-
Tek tissue culture chamber slides without FBS for 24 h. The
cells were then washed with Hank's Balanced Salt Solution
(Invitrogen-Gibco)  and  stimulated  with  10  μg/ml
hydrocortisone for 48 h. The slides were then fixed in 4%
paraformaldehyde for 15 min and washed with 10× Tris-
buffered saline (TBS) 3 times for 5 min each. Fixed cells were
incubated in a blocking buffer of 5% BSA (Proliant) and 0.1%
Triton X-100 in PBS for 30 min at room temperature. Cells
were then incubated with one or the other of the following
dilutions of primary antibodies for 1 h at room temperature:
primary  mouse  anti  human  TLR2  and  TLR4  monoclonal
TABLE 1. PRIMERS FOR REAL-TIME PCR.
Target
gene Locus Forward sequence (5’–3’) Reverse sequence (5’–3’)
Amplicon size
(bp)
VEGF NM004716 ACCCCAGGTCAGACGGACAGAA GGAATCCCCAAAGACCAGCAAT 60
TLR2 NM003264 TCTCCCATTTCCGTCTTTTT GGTCTTGGTGTTCATTATCTTC 125
TLR4 NM003266 GAAGCTGGTGGCTGTGGA TGATGTAGAACCCGCAAG 213
GAPDH NM204305 CCCCACACACATGCACTTACC TTGCCAAGTTGCCTGTCCTT 100
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2436antibodies (20 μg/ml in 5% BSA-PBS) or with mouse IgG
(control). The secondary antibodies, conjugated to Cy3, were
diluted 1:200 in 5% BSA-PBS and incubated for 1 h at room
temperature. Coverslips were washed three times in PBS for
5  min,  mounted  (Vectashield;  Vector  Laboratories,
Burlingame, CA), and viewed with a fluorescence microscope
(Zeiss microscope Imager Z1, Zeiss, Germany). The DNA-
intercalating dye, DAPI dihydrochloride, was used to stain
nuclei. For the negative control, preimmune mouse serum was
substituted for the primary antibody.
Western  blot:  Cells  challenged  with  hydrocortisone  were
lysed in RIPA buffer (150 mM NaCl, 100 mM Tris-HCl [pH
7.5], 1% deoxycholate, 0.1% SDS, 1% Triton X-100, 50 mM
NaF,  100  mM  sodium  pyrophosphate,  3.5  mM  sodium
orthovanadate, proteinase inhibitor cocktails, and 0.1 mM
phenylmethylsulfonyl  fluoride  [PMSF]).  Protein
concentration was determined using the bicinchoninic acid
(BCA) assay (Micro BCA; Pierce Biotechnology, Rockford,
IL). Equal amounts of protein were mixed with SDS-PAGE
protein loading buffer and boiled for 5 min. Proteins were
separated by sodium dodecyl sulphate–polyacrylamide gel
electrophoresis in a Tris/glycine/SDS buffer (25 mM Tris, 250
mM  glycine  and  0.1%  SDS)  and  electro-blotted  onto
nitrocellulose transfer membranes. After blocking with 5%
nonfat milk for 1 h, membranes were washed three times with
TBST for 5 min and incubated overnight with polyclonal
antibodies against TLR2, TLR4, and pIκB-α (1:1,000 dilution
in 5% nonfat milk) in TBST. GAPDH was used as the control.
After  washing  three  times  in  TBST,  membranes  were
incubated with secondary HRP-conjugated anti-mouse IgG
for 1 h. The membranes were again washed with TBST three
times,  and  one  time  in  TBS,  for  5  min  each.  Immune
complexes  were  visualized  with  an  enhanced
chemiluminescence reagent (Pierce). Results were quantified
by capturing the exposed x-ray film image and using area
measurements from image analysis software.
Enzyme-linked immunosorbent assays: The concentration of
IL-6  and  IL-8  in  the  cell  culture  supernatant  fluids  was
determined by ELISA. The assay was performed according to
manufacturer’s instructions. Results from two representative
experiments are presented as the mean±SEM of triplicate
cytokine measurements.
Statistical  analysis:  Data  are  expressed  as  mean±SEM  of
triplicates from experiments repeated three times that yielded
similar results. The statistical significance of differences was
determined  with  the  non-parametric  Wilcoxon  test  and
Student’s t test using SPSS, version 11.5. Differences were
considered statistically significant at p<0.05.
RESULTS
Modulation  of  TLR2  and  TLR4  mRNA  expression  by
hydrocortisone:  We  first  wanted  to  determine  if
hydrocortisone  treatment  altered  TLR2  and  TLR4  mRNA
expression in cells. The cells were treated with three different
concentrations (1, 10, or 100 μg/ml) hydrocortisone at 37 °C
for 48 h. The effect of hydrocortisone treatment on TLR2 and
TLR4 mRNA expression in HCFs is shown in Figure 1. The
results indicated that hydrocortisone treatment decreased the
TLRs’ mRNA expression in a dose-dependent manner.
Decreased expression of TLR2 and TLR4 protein following
hydrocortisone: The results of immunofluorescence staining
revealed moderate TLR2 and TLR4 reactivity in untreated
HCFs (Figure 2). The staining intensity of these antigens was
slightly inhibited after treatment with hydrocortisone at 10
μg/ml concentration (Figure 3).
The expression of TLR2 and TLR4 was also confirmed
by  western  blot  analysis.  We  next  evaluated  the  protein
expression in HCFs of TLR 2 and TLR4 under hydrocortisone
(10  μg/ml)  treatment.  As  evidenced  in  Figure  4A,B,  the
expression of TLR2 and TLR4 protein can be downregulated
in  HCFs  at  the  protein  level  using  western  blot  with  the
cellular protein GAPDH as the standard. The expression of
TLR2  and  TLR4  proteins  following  treatment  with
hydrocortisone was counteracted after pretreatment with anti-
TLR2 and anti-TLR4 monoclonal antibodies.
Detection of pIκB-α protein on human corneal fibroblasts by
western  blot:  The  results  of  western  blot  analysis
demonstrated  decreased  expression  of  pIκB-α  following
treatment  with  hydrocortisone.  The  expression  of  pIκB-α
following treatment with hydrocortisone was counteracted
after pretreatment with anti-TLR2 and anti-TLR4 monoclonal
antibodies (Figure 4A,B).
Pretreatment  with  specific  TLR2  and  TLR4  monoclonal
antibodies counteracted the hydrocortisone-inhibited release
of IL-6 and IL-8: HCFs were incubated at room temperature
either with anti-TLR4, anti-TLR2, both anti-TLR4 and anti-
TLR2, or IgG control antibodies for 1 h. Cells were then
Figure 1. TLR2 and TLR4 mRNA expression in hydrocortisone-
treated  HCF.  TLR2  and  TLR4  mRNA  expression  in  three
concentrations  of  hydrocortisone-treated  HCFs,  compared  with
untreated  HCFs.  Bars  represent  mean±SEM  of  3  independent
experiments. The asterisk represents a p value of <0.05, versus the
control.
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2437treated with hydrocortisone (10 μg/ml) for 48 h at 37 °C; the
supernatants were collected to evaluate the release of IL-6 and
IL-8. The results of ELISA showed that pretreatment of HCFs
with anti-TLR2 and/or anti-TLR4 inhibited the production of
IL-6 and IL-8 following exposure to hydrocortisone. Figure 4
shows that anti-TLR2 and anti-TLR4 pretreatment reverses
hydrocortisone suppression of IL-6 and IL-8 expression. In
contrast, an isotype-matched control, Ab, had no effect on the
release of IL-6 and IL-8 (Figure 5). Maximal upregulation was
observed in HCF cells treated with antibodies against both
TLR2 and TLR4. In comparison, incubation with anti-TLR2
and/or anti-TLR4 mAb had little effect on the production of
IL-6 and IL-8 without following exposure to hydrocortisone
(Figure 6).
Figure 2. The cells were treated with
anti-TLR2 or anti-TLR4 antibodies and
stained  by  Cy3  and  DAPI
dihydrochloride.  There  was  no
immunoreactivity  in  the  negative
control  (isotype  IgG).  Merge  means
overlapping DAPI and Cy3.
Figure 3. The 10 μg/ml hydrocortisone-
stimulated cells treated with anti-TLR2
and anti-TLR4 antibodies and stained
by  Cy3  and  DAPI  dihydrochloride.
There was no immunoreactivity in the
negative control (isotype IgG). Merge
means overlapping DAPI and Cy3.
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Glucocorticoid  potently  suppresses  immunity  and  is
commonly used in the treatment of a wide variety of immune
and  inflammatory  diseases  [15].  Currently,  topical
corticosteroids  are  the  main  choice  of  anti-inflammatory
agents for the management of most ocular surface immune-
mediated diseases [11,14,16]. Our previous report indicated
that hydrocortisone treatment increases mRNA expression of
TLR2 and TLR4 in human corneal epithelial cell lines (HCEC)
[17]. The results indicate that hydrocortisone may increase the
innate immunity of the HCEC through TLRs. Although the
expression  of  TLR-specific  mRNAs  of  fibroblasts  has
previously  been  studied  [5,18,19],  there  are  no  extensive
reports on the expression and function of TLRs in HCFs. In
this  work,  we  have  shown  that  TLR2  and  TLR4  mRNA
expression can be downregulated by hydrocortisone in a dose-
dependent manner. Western blotting also showed that the
protein  expression  of  TLR2  and  TLR4  was  also
downregulated following pretreatment with hydrocortisone in
Figure  4.  The  expression  of  TLR2,  TLR4,  and  pIκB-α  under
stimulation. A: Western blot analyses detect the expression of TLR2,
TLR4, and pIκB-α at the protein level in HCFs under stimulation of
10 μg/ml hydrocortisone or pretreated with anti-TLR2 and anti-
TLR4  monoclonal  antibodies.  Equal  amounts  of  proteins  were
loaded. B: Column diagrams and bars represent mean±SEM for the
scanned immunoblots (the ratio of TLRs to GAPDH. The results are
representative of three independent experiments. In the image, 10-
Hy indicates 10 μg/ml hydrocortisone. The asterisk represents a p
value of <0.05, versus untreated HCFs.
HCFs. These results suggest that hydrocortisone may suppress
the innate immunity of HCFs by inhibiting the expression of
TLRs.
Corticosteroids  inhibit  inflammation  through  various
pathways.  For  instance,  corticosteroid-induced  MAPK
phosphatase  1  dephosphorylates  and  inactivates  Jun  N-
terminal  kinase,  thereby  inhibiting  c-Jun-mediated
transcription  [15].  Corticosteroid-glucocorticoid  receptor
complex also interacts with NF-κB to block its transcription
activity [15]. As we know, recognition of pathogen-associated
molecular patterns via TLRs can lead to translocation of the
NF-κB,  with  consequent  upregulation  of  proinflammatory
cytokines, co-stimulatory molecules, and chemokines, such
as  TNF-α,  IL-6,  IL-8,  IL-18,  and  monocyte  chemotactic
protein-1 (MCP) [20,21]. Our results show that the expression
of TLR2 and TLR4 was markedly inhibited by hydrocortisone
in both mRNA and at the protein level. At the same time, the
release  of  IL-6  and  IL-8  can  also  be  inhibited  by
hydrocortisone. The results also agree with those of Lu et al.
[22], who have shown that dexamethasone, inhibited, also in
a dose-dependent manner, the release of IL-8 and MCP-1 from
human corneal fibroblasts induced by TNF-α or IL-1β. The
TLR family of receptors links the extracellular compartment,
where  contact  and  recognition  of  PAMPs  occur,  and  the
intracellular compartment, where signaling cascades leading
to cellular responses are initiated. Li and his associates [23]
have  recently  reported  that  glucocorticoid  enhanced  the
expression of TLR-2 by inhibiting the negative effect of p38
MAPK  kinase,  by  increasing  the  expression  of  the
phosphatase mitogen-activated protein kinase phosphatase-1
(MKP)-1. Silverstein et al. [24] reported that TLR2 is involved
in glucocorticoid’s protective efficacy against Gram-positive
and Gram-negative sepsis in experimental bacterial sepsis.
Anti-TLRs  antibodies  have  been  long  used  to  study  the
function of TLRs. Many reports have suggested anti-TLR
antibodies  can  inhibit  the  function  of  TLRs  [17,25,26].
Figure 5. The results of ELISA showed the release of IL-6 and IL-8
from HCFs under different stimulation. Data are the mean±SEM of
triplicates from an experiment that was repeated three times with
similar results. The asterisk indicates p<0.05 versus the control, and
p<0.05 versus 10 μg/ml hydrocortisone.
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2439However, there is no report about the impact of the use of
glucocorticoids on innate immunity in the absence of stimuli
such as LPS, poly (I: C), and so forth.
In order to further determine if the role of glucocorticoids
may relate to TLRs, the cultured HCFs were pretreated with
specific TLR2 and TLR4 monoclonal antibodies to study the
expression of TLR2, TLR4, IL-6, and IL-8. We found that the
expression of TLR2 and TLR4, and the release of IL-6 and
IL-8, which was inhibited by hydrocortisone, can be partly
counteracted  by  anti-TLR2  and  anti-TLR4  monoclonal
antibodies. For detailed analysis of the specific contribution
of TLRs, we investigated NF-κB activation in hydrocortisone-
treated HCFs. Because phosphorylation of IκB-α at Ser32 is
essential for the release of active NF-κB, phosphorylation at
this site is an excellent marker of NF-κB activation. Western
blot  analysis  revealed  that  pIkB-α  activation  was
downregulated  in  hydrocortisone-treated  HCFs,  but  the
expression can be partly counteracted by anti-TLR2 and anti-
TLR4 monoclonal antibodies. These results further indicate
that  hydrocortisone  may  suppress  the  innate  immunity  of
HCFs through TLR2 and TLR4. Yet why the glucocorticoids
can act on the TLRs is still unknown, because no ligands were
used in this study. We speculate that the possible mechanism
may be the following. 1) Glucocorticoid blocks the production
of many mediators of immune and inflammatory response,
such as cytokines, chemokines, and cell adhesion molecules.
As  a  consequence,  glucocorticoids  may  act  on  the  TLRs
through cytokines and chemokines. 2) Glucocorticoid had
direct effects on TLRs because there may exist cross-action
between  glucocorticoid  receptors  and  TLRs.  3)
Glucocorticoid had direct effects on TLRs as an unspecific
ligand  of  TLRs.  This  study  provides  insight  into  the
mechanism of the action of glucocorticoid in the treatment of
corneal  disease.  However,  the  molecular  mechanisms  of
Figure 6. The results of ELISA showed the release of IL-6 and IL-8
from  HCFs  only  pretreated  with  anti-TLR2  and  anti-TLR4
monoclonal antibodies. Data are the mean±SEM of triplicates from
an experiment that was repeated three times with similar results. The
results show that incubation with anti-TLR2 and/or anti-TLR4 mAb
had little effect on the production of IL-6 and IL-8.
glucocorticoid’s direct or indirect effects on TLR2 and TLR4
expression  still  need  further  investigation.  Although  the
cornea  is  highly  resistant  to  infections  under  normal
conditions, sight-threatening microbial infections may occur
when the corneal integrity is breached by trauma or by wear
from a contact lens. Therefore, the underlying mechanisms
that regulate corneal fibroblast cell activation are important in
the development of infectious keratitis. As we know, steroid
application has been used to promote bacterial, fungal, viral,
and  acanthamoebic  cornea  infections  of  animal  models
[22-30].  Thus,  our  results  suggest  that  hydrocortisone’s
suppression of the innate immunity of HCFs through TLRs
may explain why hydrocortisone can promote opportunistic
cornea  infection.  Our  results  indicated  the  action  of
hydrocortisone on HCFs was related to TLR2 and TLR4, but
whether other TLRs also play a crucial role requires further
investigation.
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